Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy

 Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy

Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy

Shots:

  • Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy
  • Additionally, in 2019, Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877, an autotaxin inhibitor targeting fibrosing interstitial lung diseases including IPF
  • Bridge Biotherapeutics’ pipeline includes BBT-401, being evaluated in P-II study for UC and BBT-176, a potent targeted cancer therapy for NSCLC

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bridge Biotherapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post